



1P-547-T100

## Monoclonal Antibody to HLA-B7 Phycoerythrin (PE) conjugated (100 tests)

<b>Clone:</b>	BB7.1
<b>Isotype:</b>	Mouse IgG1
<b>Specificity:</b>	The mouse monoclonal antibody BB7.1 recognizes the HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
<b>Regulatory Status:</b>	RUO
<b>Immunogen:</b>	Papain solubilised HLA-A2, B7
<b>Species Reactivity:</b>	Human, Non-Human Primates
<b>Preparation:</b>	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
<b>Storage Buffer:</b>	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
<b>Storage / Stability:</b>	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
<b>Usage:</b>	The reagent is designed for Flow Cytometry analysis of human blood cells using 10 µl reagent / 100 µl of whole blood or 10 <sup>6</sup> cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropathies. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22% of healthy Caucasian individuals.

**For laboratory research only, not for drug, diagnostic or other use.**

**Antibodies****References:**

- \*Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. *J Infect Dis.* 2001 Nov 15;184(10):1310-4.
- \*Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. *Am J Respir Crit Care Med.* 2004 Mar 15;169(6):696-702.
- \*Bhattacharya P, Sengupta S: Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B\*07 and homozygosity of HLA-DQB1\*03. *Tissue Antigens.* 2007 Oct;70(4):283-93.
- \*Harjacek M, Margetić T, Kerhin-Brkljacić V, Martinez N, Grubić Z: HLA-B\*27/HLA-B\*07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. *Clin Exp Rheumatol.* 2008 May-Jun;26(3):498-504.
- \*Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. *Clin Cancer Res.* 1999 Oct;5(10):2766-72.
- \*Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA-B7-restricted peptides of hTRT. *Int Immunol.* 2006 Dec;18(12):1707-18.
- \*Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. *Mol Cell Proteomics.* 2005 Dec;4(12):1888-97.
- \*Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchanek M, Horejsi V, Martayan A, Giacomini P: HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. *Immunol.* 2008 Oct 15;181(8):5442-50.
- \*Trapani JA, Vaughan HA, Tait BD, McKenzie IF: Immunoradiometric assay for the rapid detection of HLA-B27. *Immunol Cell Biol.* 1988 Jan;66 ( Pt 3):215-9.
- \*de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). *Clin Exp Immunol.* 2002 Jun;128(3):525-31.
- \*Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. *Proc Natl Acad Sci U S A.* 1989 Apr;86(7):2361-4.
- \*Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. *Cancer Res.* 2001 Sep 15;61(18):6868-75.
- \*Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. *Proc Natl Acad Sci U S A.* 1993 Dec 1;90(23):11307-11.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at [www.exbio.cz](http://www.exbio.cz).

**For laboratory research only, not for drug, diagnostic or other use.**

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic  
Tel: +420 261 090 666 | Fax: +420 261 090 660 | [orders@exbio.cz](mailto:orders@exbio.cz) | [www.exbio.cz](http://www.exbio.cz)